• / Free eNewsletters & Magazine
  • / My Account
Home>Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

3party Content

Sat, 30 Aug 2014

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.